Birgit Funke

Dr. Birgit Funke


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2014 in Genome Biology
Verified
Journal Article
Open access
PDF file
CBCatherine A. Brownstein
Catherine A. Brownstein
ABAlan H. Beggs
Alan H. Beggs
NHNils Homer
Nils Homer
BMBarry Merriman
Barry Merriman
TYTimothy W Yu
Timothy W Yu
DMDavid M Margulies
David M Margulies
Background: There is tremendous potential for genome sequencing to improve clinical diagnosis and care once it becomes routinely accessible, but this will require formalizing research methods into clinical best practices in the areas of sequence data generation, analysis, interpretation and reporting. The CLARITY Challenge was designed to spur convergence in methods for diagnosing genetic disease starting from clinical case history and genome sequencing data. DNA samples were obtained from three families with heritable genetic disorders and genomic sequence data were donated by sequencing platform vendors. The challenge was to analyze and interpret these data with the goals of identifying disease-causing variants and reporting the findings in a clinically useful format. Participating contestant groups were solicited broadly, and an independent panel of judges evaluated their performance. Results: A total of 30 international groups were engaged. The entries reveal a general convergence of practices on most elements of the analysis and interpretation process. However, even given this commonality of approach, only two groups identified the consensus candidate variants in all disease cases, demonstrating a need for consistent fine-tuning of the generally accepted methods. There was greater diversity of the final clinical report content and in the patient consenting process, demonstrating that these areas require additional exploration and standardization. Conclusions: The CLARITY Challenge provides a comprehensive assessment of current practices for using genome sequencing to diagnose and report genetic diseases. There is remarkable convergence in bioinformatic techniques, but medical interpretation and reporting are areas that require further development by many groups.

1 February 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
DJDaniel M. Jordan
Daniel M. Jordan
AKAdam Kiezun
Adam Kiezun
SBSamantha M. Baxter
Samantha M. Baxter
VAVineeta Agarwala
Vineeta Agarwala
RGRobert C. Green
Robert C. Green
SSShamil R. Sunyaev
Shamil R. Sunyaev

1 May 2010 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
RZRebekah S. Zimmerman
Rebekah S. Zimmerman
SCStephanie Cox
Stephanie Cox
NLNeal K. Lakdawala
Neal K. Lakdawala
ACAllison Cirino
Allison Cirino
DMDebora Mancini-Dinardo
Debora Mancini-Dinardo
BFBirgit Funke
Birgit Funke
Purpose: Genetic tests for the most commonly mutated genes in dilated cardiomyopathy (DCM) can confirm a clinical diagnosis in the proband and inform family management. Presymptomatic family members can be identified, allowing for targeted clinical monitoring to minimize adverse outcomes. However, the marked locus and allelic heterogeneity associated with DCM have made clinical genetic testing challenging. Novel sequencing platforms have now opened up avenues for more comprehensive diagnostic testing while simultaneously decreasing test cost and turn around time. Methods: By using a custom design based on triplicate resequencing and separate genotyping of known disease-causing variants, we developed the DCM CardioChip for efficient analysis of 19 genes previously implicated in causing DCM. Results: The chip's analytical sensitivity for known and novel substitution variants is 100% and 98%, respectively. In screening 73 previously tested DCM patients who did not carry clinically significant variants in 10 genes, 7 variants of likely clinical significance were identified in the remaining 9 genes included on the chip. Compared with traditional Sanger-based sequencing, test cost and turn around time were reduced by ∼50%. Conclusions: The DCM CardioChip is a highly efficient screening test with a projected clinical sensitivity of 26–29%.

1 November 2014 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
DMDiana Mandelker
Diana Mandelker
SASami Amr
Sami Amr
TPTrevor J Pugh
Trevor J Pugh
SGSivakumar Gowrisankar
Sivakumar Gowrisankar
RSRimma Shakhbatyan
Rimma Shakhbatyan
BFBirgit Funke
Birgit Funke

1 November 2010 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
SGSivakumar Gowrisankar
Sivakumar Gowrisankar
JLJordan P. Lerner-Ellis
Jordan P. Lerner-Ellis
SCStephanie Cox
Stephanie Cox
EWEmily T. White
Emily T. White
MMMegan Manion
Megan Manion
BFBirgit Funke
Birgit Funke

16 December 2015 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
OCOzge Ceyhan‐Birsoy
Ozge Ceyhan‐Birsoy
TPTrevor J Pugh
Trevor J Pugh
MBMark J. Bowser
Mark J. Bowser
EHElizabeth Hynes
Elizabeth Hynes
AFAshley L. Frisella
Ashley L. Frisella
BFBirgit Funke
Birgit Funke
Background: Diagnostic testing for genetic cardiomyopathies has undergone dramatic changes in the last decade with next generation sequencing (NGS) expanding the number of genes that can be interrogated simultaneously. Exon resolution copy number analysis is increasingly incorporated into routine diagnostic testing via cytogenomic arrays and more recently via NGS. While NGS is an attractive option for laboratories that have no access to array platforms, its higher false positive rate requires weighing the added cost incurred by orthogonal confirmation against the magnitude of the increase in diagnostic yield. Although copy number variants (CNVs) have been reported in various cardiomyopathy genes, their contribution has not been systematically studied.Methods: We performed single exon resolution NGS‐based deletion/duplication analysis for up to 46 cardiomyopathy genes in >1400 individuals with cardiomyopathies including HCM, DCM, ARVC, RCM, and LVNC.Results and Conclusion: Clinically significant deletions and duplications were identified in only 9 of 1425 (0.63%) individuals. The majority of those (6/9) represented intragenic events. We conclude that the added benefit of exon level deletion/duplication analysis is low for currently known cardiomyopathy genes and may not outweigh the increased cost and complexity of incorporating it into routine diagnostic testing for these disorders.